| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 荣昌生物制药（烟台）股份有限公司由王威东先生领导的烟台荣昌制药股份有限公司和留美科学家房健民博士于2008年共同创立。荣昌生物总部位于中国山东省烟台市，在中国和美国均设有实验研究机构和办事处。荣昌生物致力于发现、开发、生产和商业化同类首创、同类最佳的生物药物，针对自身免疫、肿瘤、眼科等重大疾病领域创制出一批具有重大临床价值的生物新药。 我们的使命是针对自身免疫、肿瘤、眼科等重大疾病领域，发现、开发、生产及商业化同类首创、同类最佳的生物药物，创造临床价值，满足全球尚未被满足的重大临床需求，实现公司价值的最大化。 我们的愿景是成为中国领先、国际一流的生物制药公司。 | ||||||||||||||||||||||||
| Main Business | 发现、开发与商业化创新、有特色的同类首创（first-in-class）与同类最佳（best-in-class）生物药，以创造药物临床价值为导向，为自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域提供安全、有效、可及的临床解决方案，以满足大量尚未被满足的临床需求 | ||||||||||||||||||||||||
| Legal Representative | 王威东 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 温庆凯 | ||||||||||||||||||||||||
| Solicitors | 北京市金杜律师事务所 | ||||||||||||||||||||||||
| Auditors | 安永华明会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0535-3573685 | ||||||||||||||||||||||||
| Fax No | 0535-6113517 | ||||||||||||||||||||||||
| Website | www.remegen.cn | ||||||||||||||||||||||||
| rcsw@remegen.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 31/03/2022 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -2.800 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 6.315 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 5.999B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |